Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
714.6 INR | +0.23% | -1.61% | -10.58% |
05-01 | Rossari Biotech's Consolidated Profit Climbs in FIscal Q4 | MT |
04-30 | Transcript : Rossari Biotech Limited, Q4 2024 Earnings Call, Apr 30, 2024 |
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 29.62 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.58% | 470M | C+ | ||
+17.73% | 66.69B | A- | ||
+16.33% | 41.24B | B+ | ||
+20.03% | 25.89B | A- | ||
+12.78% | 19.81B | C+ | ||
+0.85% | 17.48B | B+ | ||
-21.87% | 15.86B | A- | ||
+2.32% | 15.35B | B+ | ||
-10.29% | 15.23B | C+ | ||
-22.30% | 13.36B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSSARI Stock
- ROSSARI Stock
- Ratings Rossari Biotech Limited